AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
AbbVie today announced that it has submitted applications seeking approval for SKYRIZI® (risankizumab-rzaa, 150 mg) to the ...
Read more
Tag: Abbvie
News about Abbvie
AbbVie Announces Extension of Review for Supplemental NDA of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis
AbbVie announced that the U.S. Food and Drug Administration (FDA) has extended the review period for ...
Read more
U.S. FDA Accepts AbbVie’s NDA for Atogepant for the Preventive Treatment of Migraine
If approved, atogepant will be the first and only oral CGRP receptor antagonist specifically developed for ...
Read more